Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04526353

Early Oxybutinin Treatment for Boys With Posterior Urethral Valves

Boys with posterior urethral valves have bladder dysfunction of varying severity. Early treatment of these children with anticholinergics is recommended by some teams, although there have never been any clear studies on the subject. To our knowledge, no comparative study of the evolution of valve bladders with or without treatment has been carried out to date.

Anticholinergic treatment, although it may be beneficial in patients with abnormal bladder function, such as the neurologic bladders ( in Spina Bifida) for example, may have side effects and may not be of benefit for this valve population. The evolution of the valves could be spontaneously favorable.

This study would be the first randomized clinical trial of early therapeutic drug intervention in the posterior urethral valve population.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Male Urogenital Diseases Urogenital Diseases

Age range

3 month–6 month

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

About this study

Posterior urethral valves (VUPs) are the leading cause of subvesical obstruction in children with an incidence between 1 / 3,000 to 1 / 8,000 births. 25-45% of patients will have chronic renal failure and 10-20% will require a transplant. The association between long-term prognosis and bladder dysfunction is well known, leading many teams to suggest early initiation of treatment with anticholinergics.

However, this treatment has never been properly evaluated. In fact, a single study carried out in boys with valves taking oxybutynin from the age of 3 months to 2 years without a control group concluded that "the early use of anticholinergics in boys with VUP presenting high voiding pressures and low bladder capacity has a beneficial effect on bladder function. It is true that in children with neurologic bladders as in Spina Bifida, early treatment with anticholinergics seems to provide a benefit, but VUPs are not strictly speaking neurologic bladders. In addition, treatment with anticholinergics can have side effects and could even be harmful to the bladder, leading to myogenic bankruptcy. The only way to properly assess oxybutynin in this population is to conduct a prospective randomized study.

The proposed study includes a group treated with oxybutynin and a group without. Boys who have had valve resection for VUP within the first three months of life and who present an abnormal urodynamic assessment 3 months after valve resection will be included. Oxybutynin will be given at a dose of 0.1 mg / kg 2x / day, as syrup, in the treatment group. The control group will not have any treatment affecting bladder function. The pharmacokinetics of oxybutynin will be studied. Several urodynamic parameters including capacity or volume, voiding pressure and compliance will be studied. The objective is to perform a composite analysis that can reflect the complex functioning of the bladder. The children included will have urodynamics at the end of the study, after 9 months of treatment. The performance of urodynamic examinations will be standardized and there will be an external centralized analysis to validate the urodynamic results.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Boys
  • Aged 3 to 6 months
  • Diagnosed with posterior urethral valves, and having undergone valve resection within the first 3 months of life
  • Children who have had their valve resection at least 3 months before inclusion
  • Having undergone urodynamic studies between 10 weeks and 6 months of age andshowing abnormal urodynamics, notably: high voiding pressure (>60cm H2O)/ small capacity bladder (<70% expected bladder volume)and for those without pop-off mechanisms, poor compliance (<10ml/cmH2O)/
  • Holders of parental authority affiliated to French national health insurance
  • With informed consent signed by holders of parental authority

Exclusion criteria

  • Boys with posterior urethral valves and normal urodynamics or no urodynamic assessment
  • Boys in whom urodynamic assessment is not possible for medical or anatomical reasons
  • Boys requiring dialysis before the age of 3 months
  • Contra-indication to oxybutynin such as hypersensitivity to oxybutynin or any of the excipients, digestive obstruction, occlusive or sub-occlusive syndrome, megacolon, digestive stasis, intestinal atony, paralytic ileus, ulcerative colitis, Hemorrhagic rectocolitis, Crohn's disease, Inflammatory bowel disease, Inflammatory organic colopathy, myasthenia, congenital glaucoma

Treatment and study plan

Oxybutynin 1 mg/ml Syrup

Drug

The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.

The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children <1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012

Primary outcomes

  1. success of treatment defined by the association of the three events

    Time frame: 9 months after inclusion

    composite endpoints where the success of treatment at 9 months after inclusion is defined by the association of the three following events:

    • Voiding pressure <60 cmH2O AND
    • Bladder Volume ≥70% of theoretical value AND
    • for those without pop-off mechanisms, Bladder compliance >10mL/cmH2O A failure of treatment will be defined as the absence of at least one of these events.

    In presence of a pressure pop-off mechanism, only voiding pressure and bladder volume will be analyzed.

Secondary outcomes

  1. Proportion of adverse events in each group

    Time frame: through study completion, an average of 9 months

  2. Type of adverse events in each group

    Time frame: through study completion, an average of 9 months

    adverse event or serious adverse event

  3. Incidence of urinary tract infections in each group

    Time frame: through study completion, an average of 9 months

  4. Compliance with treatment

    Time frame: 9 months after inclusion

    Compliance with treatment will be evaluated through the proportion of oxybutynin treatment interruption

  5. Sonographic changes

    Time frame: 9 months after inclusion

    Sonographic changes will be expressed as a degree of hydronephrosis at 12-15 months of life (9 months after inclusion)

  6. Area under the plasma concentration versus time curve (AUC) of oxybutynin in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Area under the plasma concentration versus time curve (AUC) of oxybutinin in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  7. Peak Plasma Concentration (Cmax) of oxybutynin in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Peak Plasma Concentration (Cmax) of oxybutynin in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  8. Minimum plasma concentration (Cmin) of oxybutynin in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Minimum plasma concentration (Cmin) of oxybutynin in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  9. Half-life of oxybutynin in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Half-life of oxybutynin in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  10. Area under the plasma concentration versus time curve (AUC) of desethyloxybutynin (metabolite) in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Area under the plasma concentration versus time curve (AUC) of desethyloxybutynin (active metabolite) in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  11. Peak Plasma Concentration (Cmax) of desethyloxybutynin (metabolite) in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Peak Plasma Concentration (Cmax) of desethyloxybutynin (active metabolite) in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  12. Minimum plasma concentration (Cmin) of desethyloxybutynin (metabolite) in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Minimum plasma concentration (Cmin) of desethyloxybutynin (active metabolite) in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  13. Half-life of desethyloxybutynin (metabolite) in treated boys over treatment

    Time frame: through study completion, an average of 9 months

    Half-life of desethyloxybutynin (active metabolite) in treated boys over treatment. Pharmacokinetic samples (6 points from Cmin to H+3h) at 2 weeks, 3 and 9 months after inclusion will be used to study and determine the pharmacokinetic parameters. In order to avoid having to take blood sample from the child several times, it is proposed to use a small venous catheter during the time of the pharmacokinetic samples

  14. creatinine clearance in each group

    Time frame: through study completion, an average of 9 months

Study contacts

Contact information is provided by the study sponsor or research team.

Aurore A CAPELLI, PhD

CONTACT

[email protected]

05 57 82 08 77

Luke L HARPER, MD

CONTACT

[email protected]

05 56 79 56 17

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Prospective Randomized Clinical Trial of Early Oxybutinin Treatment for Boys With Posterior Urethral Valves

Acronym: PRETIPUV

Important dates

Study start
2020
Primary completion
2028
Study completion
2028
First posted
Aug 25, 2020
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.